Salute e Benessere

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase…

Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million in milestone payments relating to equity financing pursuant to amendment to license and collaboration agreement with CTTQ.Proceeds from financing to be primarily used to advance Inventiva's Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. More than 1,100 patients...

Nomination Committee appointed for SciBase Holding's Annual General Meeting in…

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on June 13, 2024. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding onJune 13, 2024. The Annual General Meeting...

Discover Medtecs' Latest Innovations in Medical Protection and Sustainability at…

Medtecs has made significant strides in promoting sustainability by using biodegradable materials for accessories such as shoe covers and bouffant caps, while also adopting automation technologies that enhance production efficiency and product quality. Key innovations include automated systems such as a fabric inspection system, flatbed cutter, mold machine, and pocket stitching machine. By reducing reliance on manual labor and standardizing production, Medtecs is improving its capacity and…

Nicox and Soleus Sign $16.5 million Royalty and Equity Financing

Press Release Nicox and Soleus Sign $16.5 million Royalty and Equity FinancingGross proceeds of $15 million (€13.7 million) for the sale of Nicox's net share of the VYZULTA royalty to SoleusSoleus investing $1.5 million (€1.37 million) in Nicox shares, issued at €0.3144 per share, representing a 20% premium to the closing price on October 11, 2024, with attached warrants valued at $0.75 million (€0.69 million) at an exercise price of €0.5240 per share, representing a 100% premium to...

Embark on a Journey of Holistic Wellbeing at Banyan Tree Dubai's Brand-New Spa

Upon entering the spa, guests can engage with nature through features such as the Tranquility Garden and barefoot pathways, allowing you to feel truly connected and unlock a sense of groundedness. One of the spa's standout features is the Rainforest experience, a multisensory journey comprising a rain walk with ceiling and wall spa water jets, steam and sauna rooms, and a variety of invigorating shower experiences. Upon entering the spa, guests can engage with nature through features such as...

Majority of children with spinal muscular atrophy (SMA) treated with Roche's…

Positive data confirm Evrysdi efficacy and safety in children first treated pre-symptomatically before six weeks of age, with most achieving motor milestones similar to children without SMAAll children were able to swallow and feed orally, with none requiring permanent ventilationEvrysdi is the only non-invasive SMA therapy and is approved in over 100 countries, with more than 16,000 people with SMA treated globallyBasel, 14 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY)...

Novotech Awarded Frost & Sullivan's 2024 Global Company of the Year Award for…

Novotech enables biotech companies to navigate the complex global regulatory landscape by leveraging its extensive expertise in local regulations and deep understanding of cultural nuances. With 34 office locations across the United States, Europe, and the Asia-Pacific region—including Australia, China, India, Malaysia, New Zealand, and Thailand—Novotech's global presence ensures that biotech firms receive tailored solutions that meet their unique needs. Additionally, Novotech distinguishes…

UEG Week: Novel procedure combined with semaglutide may eliminate insulin…

Globally, T2D affects 422 million people, with obesity recognised as a significant risk factor. While insulin therapy is commonly used to manage blood sugar levels in T2D patients, it can result in side effects such as weight gain and further complicate diabetes management. A need therefore exists for alternative treatment strategies. Globally, T2D affects 422 million people, with obesity recognised as a significant risk factor. While insulin therapy is commonly used to manage blood sugar...

90th CMEF in Shenzhen Showcases Global MedTech Innovations and Insights

A notable feature of this year's exhibition is a strategic agreement. In June 2025, RSE will host THE HEALTH INDUSTRY SERIES – ASEAN (tHIS ASEAN) co-located with APHM. The Southeast Asian healthcare market is set for rapid expansion, with an expected annual growth rate of 10-12%. This partnership seeks to unite healthcare professionals and industry leaders in Southeast Asia, encouraging cooperation and progress to improve global health standards. A notable feature of this year's exhibition is…

SkylineDx Announces Data from Largest Prospective Multi-Center Melanoma Gene…

The trial, conducted at nine academic sites in the United States has been successfully led by three principal investigators Dr. V. Sondak M.D., Chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, Dr. T. Hieken, M.D., Surgical Oncologist and Professor of Surgery, Mayo Clinic, and Dr. M. Egger M.D., M.P.H., Associate Professor, Surgical Oncologist UofL Health Brown Cancer Center Louisville. The trial validated the predictive power of the CP-GEP (Clinical-Pathologic and Gene…

World Thrombosis Day raises global awareness of blood clot dangers through…

The campaign has partnered with more than 6,000 organizations worldwide to implement impactful initiatives. This year, World Thrombosis Day emphasizes the impact on women's health with the launch of a new global survey aimed at understanding women's awareness of their health risks. The campaign has partnered with more than 6,000 organizations worldwide to implement impactful initiatives. This year, World Thrombosis Day emphasizes the impact on women's health with the launch of a new global...

BioVaxys Announces Marketing Program

As consideration for the Services, the Company will pay OTB a cash fee in advance in the amount of $130,000. The Company will not issue any securities to OTB as compensation for the Services. Pursuant to the terms of the Agreement, OTB will provide the Services in order to communicate information about the Company, including, but not limited to: As consideration for the Services, the Company will pay OTB a cash fee in advance in the amount of$130,000. The Company will not issue any...

Voting Rights and Shares Capital of the Company

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Oct.11, 2024(GLOBE NEWSWIRE) --Paris, France, October 11, 2024Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDate Number of Shares OutstandingTotal number of...

Innocan Pharma's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis…

In two ongoing cases, dogs suffering from osteoarthritis who were treated with LPT-CBD after failing to respond to non-steroidal anti-inflammatory drugs (NSAIDs) and oral CBD, showed noticeable pain relief, substantially improved mobility and increased, clearly noticeable well-being. Both dogs remained on LPT-CBD treatment for 2 and 2.5 years respectively after their owners reported significant improvement in quality of life when receiving the treatment in addition to conventional treatments…

Pharmaceutical Filtration Industry Forecasts $18.1 Billion Market Size by 2029

The global pharmaceutical filtration market is comprehensively analyzed based on various segments including type (sterile and non-sterile), product (filters, systems, others), mechanism (surface filtration, depth filtration, crossflow filtration), category (liquid and gas filtration, air filtration), and technology (ultrafiltration, microfiltration, nanofiltration, others). The market also considers application areas such as drug manufacturing, purification, and quality control. Regionally, the…

Cell Therapy 2.0: The Rise of Automation and Closed Systems

This report explores the automated and closed cell therapy market, highlighting its current and future potential. It analyzes the factors driving growth, challenges, and opportunities. The report also: This report explores the automated and closed cell therapy market, highlighting its current and future potential. It analyzes the factors driving growth, challenges, and opportunities. The report also: • Predicts market trends up to 2029 • Examines the competitive landscape • Analyzes...

PCR Technologies Market to Hit USD 21.89 Billion by 2030 with 7.7% CAGR |…

Browse in-depth TOC on "PCR Technologies Market" Browse in-depth TOC on "PCR Technologies Market" 237 - Tables 68 - Figures 304 - Pages Recent improvements in PCR technology are, therefore, increasingly changing the industry landscape through a combination of innovative developments and regulatory shifts. A great new trend in the industry involves an increasing use of digital PCR (dPCR), ideally used in high sensitivity and accuracy in the detection and quantification of…

ChemoMetec's potential acquisition of Ovizio Imaging Systems SA

ANNOUNCEMENT NO. 278 11 October 2024ChemoMetec's potential acquisition of Ovizio Imaging Systems SAAs mentioned in company announcement no. 276, ChemoMetec has made an indicative purchase offer for the Belgian company Ovizio Imaging Systems SA. As also stated in the announcement, ChemoMetec expected to complete the due diligence within three weeks and most likely to complete the acquisition, if the outcome was positive.The mentioned due diligence and negotiations on the final...

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the…

Halle (Saale) / Munich, Germany, October 11, 2024– Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company's abstract “Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat...

EveryMatrix completes the recommended public cash offer to the shareholders of…

Shares tendered and acquired outside the Offer as well as sale commitments Shares tendered and acquired outside the Offer as well as sale commitments 3,046,040 shares, corresponding to 85.65 per cent of all shares and votes in Fantasma, were tendered in the Offer during the acceptance period that ended on10 October 2024. Following the announcement of the Offer, EveryMatrix has acquired 150,000 shares, corresponding to 4.22 per cent of all shares and votes in Fantasma, outside the Offer...

Hugues Péribère of Overseed Named in the 2024 Business Worldwide Magazine CEO…

Péribère's achievement highlights his exemplary work in leading Overseed, a pioneering force in France's biopharmaceutical landscape, particularly in medical cannabis production. Under his leadership, Overseed has emerged as a frontrunner in the development of pharmaceutical-grade medical cannabis in France. With expertise in genetics, agronomy, and pharmaceutical chemistry, Overseed is set to become the first French manufacturer of 100% cannabis-based medicines, helping to shape the future of…

Press Release: Sanofi in discussions to sell a controlling stake in Opella

Sanofi in discussions to sell a controlling stake in OpellaParis, October 11, 2024 .Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business.Should these discussions lead to a positive outcome, any agreement would be subject to the completion of the necessary social processes.Further updates on the potential separation of Opella will be provided in due course,...

FDA approves Roche's Itovebi, a targeted treatment for advanced hormone…

Approval is based on Phase III INAVO120 results, showing the Itovebi™(inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting 1 This approval helps address an urgent unmet need in breast cancer for people with aPIK3CAmutation, one of the most commonly mutated genes in HR-positive disease, associated with poor prognosis 2,3Itovebi is Roche's first targeted therapy approved for...

NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare…

NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Aarhus, Denmark, 11 October 2024– NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today announces that three abstracts have been accepted for oral presentation, and a fourth abstract selected for poster presentation, at the American Association of...

Altri Comunicati